K-745

K-745 is a preclinical-stage therapeutic candidate being developed by Kallyope for the treatment of neurological disorders. The program is part of Kallyope's proprietary drug discovery platform, which focuses on the gut-brain axis to identify novel therapeutic targets. By modulating specific cells and circuits in the gastrointestinal tract that communicate with the brain, Kallyope aims to develop small molecule treatments for central nervous system (CNS) conditions. As of late 2024, the specific molecular target and mechanism of action for K-745 remain undisclosed, although the company's platform typically emphasizes gut-restricted or gut-brain signaling small molecules.